Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

16.32 -0.43 (-2.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus Inc

< Previous 1 2 3 4 5 6 7 Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recap: Evolus Q4 Earnings
Via Benzinga
Earnings Outlook For Evolus
Via Benzinga
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
From Evolus
Via Business Wire
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Evolus Announces Results from European Head-to-Head Filler Trial
From Evolus
Via Business Wire
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
From Evolus
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped... 
Via Benzinga
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing... 
Via Benzinga
Exposures Product Safety
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
From Evolus
Via Business Wire
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
From Evolus
Via Business Wire
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
Exposures Product Safety
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.